Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Cahn

Showing results (1-10 of 207) with videos related to

Pageof 21
Sort By:
AIDS (London, England)|August 1, 2002
AIDS and globalization: the Argentinean crisisPedro Cahn
Expert Opinion on Investigational Drugs|December 19, 2003
Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapyPedro Cahn
Medicina|April 16, 2005
[Antiretroviral (ARV) therapy. Advances and deficits left by the year 2004]Pedro Cahn
Current Opinion in HIV and AIDS|May 19, 2017
Candidates for inclusion in a universal antiretroviral regimen: dolutegravirPedro Cahn
Retrovirology|December 5, 2006
Beyond the first 25 years: The International AIDS Society and its role in the global response to AIDSPedro Cahn, Craig McClure
The Journal of Infectious Diseases|March 28, 2013
Boosting HIV treatment options: good news, new challengesPedro Cahn, Omar Sued
Lancet (London, England)|April 17, 2007
Raltegravir: a new antiretroviral class for salvage therapyPedro Cahn, Omar Sued
Lancet (London, England)|October 31, 2006
AIDS 2006 and beyondPedro Cahn, Craig McClure
Lancet (London, England)|July 29, 2008
Strengthening accountability in the global response to HIVPedro Cahn, Craig McClure
Lancet Regional Health. Americas|February 13, 2023
Latin America Priorities after 40 years of the beginning of the HIV pandemicOmar Sued, Pedro Cahn
Pageof 21

Showing results (1-10 of 207) with videos related to

Sort By:
Pageof 21
AIDS (London, England)|August 1, 2002
AIDS and globalization: the Argentinean crisisPedro Cahn
Expert Opinion on Investigational Drugs|December 19, 2003
Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapyPedro Cahn
Medicina|April 16, 2005
[Antiretroviral (ARV) therapy. Advances and deficits left by the year 2004]Pedro Cahn
Current Opinion in HIV and AIDS|May 19, 2017
Candidates for inclusion in a universal antiretroviral regimen: dolutegravirPedro Cahn
Retrovirology|December 5, 2006
Beyond the first 25 years: The International AIDS Society and its role in the global response to AIDSPedro Cahn, Craig McClure
The Journal of Infectious Diseases|March 28, 2013
Boosting HIV treatment options: good news, new challengesPedro Cahn, Omar Sued
Lancet (London, England)|April 17, 2007
Raltegravir: a new antiretroviral class for salvage therapyPedro Cahn, Omar Sued
Lancet (London, England)|October 31, 2006
AIDS 2006 and beyondPedro Cahn, Craig McClure
Lancet (London, England)|July 29, 2008
Strengthening accountability in the global response to HIVPedro Cahn, Craig McClure
Lancet Regional Health. Americas|February 13, 2023
Latin America Priorities after 40 years of the beginning of the HIV pandemicOmar Sued, Pedro Cahn
Pageof 21